The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
The way forward in HCV treatment — finding the right path
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome
Choo, Q.-L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., & Houghton, M. (1989) · Science · doi:10.1126/science.2523562 · Cited by 6,875
Self-citationPeginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Self-citationMcHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Poynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)07124-4 · Cited by 2,318
Self-citationSchaff, Z., & Csmos, G. (1994) · Cited by 1,868
Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa
Davis, G. L., Balart, L. A., Schiff, E. R., Lindsay, K., Bodenheimer, H. C., Perrillo, R. P., Carey, W., Jacobson, I. M., Payne, J., Dienstag, J. L., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212203 · Cited by 1,633
Torriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., Lissen, E., Gonzalez-García, J., Lazzarin, A., Carosi, G., Sasadeusz, J., Katlama, C., Montaner, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040842 · Cited by 1,233
Self-citationPeginterferon Alfa-2a in Patients with Chronic Hepatitis C
Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M.-Y., Gane, E., O'Grady, J., Reichen, J., Diago, M., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432301 · Cited by 1,220
Self-citationMartell, M., Esteban, J. I., Quer, J., Genescà, J., Weiner, A., Esteban, R., Guardia, J., & Gómez, J. (1992) · Journal of Virology · doi:10.1128/jvi.66.5.3225-3229.1992 · Cited by 930
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
Lamarre, D., Anderson, P. C., Bailey, M., Beaulieu, P., Bolger, G., Bonneau, P., Bös, M., Cameron, D. R., Cartier, M., Cordingley, M. G., et al. (2003) · Nature · doi:10.1038/nature02099 · Cited by 917
Global surveillance and control of hepatitis C
(1999) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.1999.6120139.x · Cited by 904
Unravelling hepatitis C virus replication from genome to function
Lindenbach, B. D., & Rice, C. M. (2005) · Nature · doi:10.1038/nature04077 · Cited by 820
Structural biology of hepatitis C virus
Penin, F., Dubuisson, J., Rey, F. A., Moradpour, D., & Pawlotsky, J.-M. (2004) · Hepatology · doi:10.1002/hep.20032 · Cited by 683
Lindsay, K. L., Trepo, C., Heintges, T., Shiffman, M. L., Gordon, S. C., Hoefs, J. C., Schiff, E. R., Goodman, Z. D., Laughlin, M., Yao, R., et al. (2001) · Hepatology · doi:10.1053/jhep.2001.26371 · Cited by 668
Treating viral hepatitis C: efficacy, side effects, and complications
Manns, M. P., Wedemeyer, H., & Cornberg, M. (2006) · Gut · doi:10.1136/gut.2005.076646 · Cited by 659
Self-citationSarrazin, C., Kieffer, T. L., Bartels, D., Hanzelka, B., Müh, U., Welker, M., Wincheringer, D., Zhou, Y., Chu, H., Lin, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.037 · Cited by 616
Self-citationThe SF-36 Health Survey: Development and Use in Mental Health Research and the IQOLA Project
Ware, Jr., & Gandek, B. (1994) · International Journal of Mental Health · doi:10.1080/00207411.1994.11449283 · Cited by 597
Projecting future complications of chronic hepatitis C in the United States
Davis, G. L., Albright, J. E., Cook, S. F., & Rosenberg, D. M. (2003) · Liver Transplantation · doi:10.1053/jlts.2003.50073 · Cited by 576
Muir, A. J., Bornstein, J. D., & Killenberg, P. G. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032502 · Cited by 541
Poynard, T., Bedossa, P., Chevallier, M., Mathurin, P., Lemonnier, C., Trepo, C., Couzigou, P., Payen, J. L., Sajus, M., Costa, J. M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322201 · Cited by 458
Shiffman, M. L., Di Bisceglie, A. M., Lindsay, K. L., Morishima, C., Wright, E. C., Everson, G. T., Lok, A. S., Morgan, T. R., Bonkovsky, H. L., & Lee, W. M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.014 · Cited by 453
Chen, L., Borozan, I., Feld, J., Sun, J., Tannis, L.-L., Coltescu, C., Heathcote, J., Edwards, A. M., & McGilvray, I. D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.01.059 · Cited by 453
Sepkowitz, K. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442306 · Cited by 438
Global surveillance and control of hepatitis C
Lavanchy, D., Purcell, R. H., Hollinger, F. B., et al. (1999) · UCL Discovery (University College London) · Cited by 433
Challenges and successes in developing new therapies for hepatitis C
De Francesco, R., & Migliaccio, G. (2005) · Nature · doi:10.1038/nature04080 · Cited by 411
Reesink, H. W., Zeuzem, S., Weegink, C. J., Forestier, N., van Vliet, A., van de Wetering de Rooij, J., McNair, L., Purdy, S., Kauffman, R., Alam, J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.07.013 · Cited by 401
Self-citationAmerican Gastroenterological Association Technical Review on the Management of Hepatitis C
Dienstag, J. L., & McHutchison, J. G. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.010 · Cited by 384
Epidemiology of Hepatitis C Virus (HCV) Infection
Sy, T., & Jamal, M. M. (2006) · International Journal of Medical Sciences · doi:10.7150/ijms.3.41 · Cited by 361
Folgori, A., Capone, S., Ruggeri, L., Meola, A., Sporeno, E., Ercole, B. B., Pezzanera, M., Tafi, R., Arcuri, M., Fattori, E., et al. (2006) · Nature Medicine · doi:10.1038/nm1353 · Cited by 322
Prospects for a vaccine against the hepatitis C virus
Houghton, M., & Abrignani, S. (2005) · Nature · doi:10.1038/nature04081 · Cited by 312
Self-citationSarrazin, C., Rouzier, R., Wagner, F., Forestier, N., Larrey, D., Gupta, S. K., Hussain, M., Shah, A., Cutler, D., Zhang, J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.01.041 · Cited by 310
Self-citationHepatocellular carcinoma: Recent trends in Japan
Kiyosawa, K., Umemura, T., Ichijo, T., Matsumoto, A., Yoshizawa, K., Gad, A., & Tanaka, E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.012 · Cited by 308
In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061
Lin, C., Lin, K., Luong, Y.-P., Rao, B. G., Wei, Y.-Y., Brennan, D. L., Fulghum, J. R., Hsiao, H.-M., Ma, S., Maxwell, J. P., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313020200 · Cited by 288
Lin, C., Kwong, A., & Perni, R. (2006) · Infectious Disorders - Drug Targets · doi:10.2174/187152606776056706 · Cited by 243
Hepatitis C therapeutics: current status and emerging strategies
Tan, S.-L., Pause, A., Shi, Y., & Sonenberg, N. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd937 · Cited by 197
Barriers to the treatment of hepatitis C: Patient, provider, and system factors
Morrill, J. A., Shrestha, M., & Grant, R. W. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.0161.x · Cited by 180
Ma, S., Boerner, J. E., TiongYip, C., Weidmann, B., Ryder, N. S., Cooreman, M. P., & Lin, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00310-06 · Cited by 163
Nevens, F., Roskams, T., Vlierberghe, H. V., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50474 · Cited by 132
McHutchison, J. G., Bacon, B. R., Gordon, S. C., Lawitz, E., Shiffman, M., Afdhal, N. H., Jacobson, I. M., Muir, A. J., Al-Adhami, M., Morris, M. L., et al. (2007) · Hepatology · doi:10.1002/hep.21773 · Cited by 114
Kanda, T., Steele, R., Ray, R., & Ray, R. B. (2006) · Journal of Virology · doi:10.1128/jvi.01496-06 · Cited by 97
The culture of designing hepato-biliary randomised trials
Gluud, C. N. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.12.006 · Cited by 79
Lin, K. W., Kwong, A. D., & Lin, C. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4784-4792.2004 · Cited by 79
The nature of interferon-α resistance in hepatitis C virus infection
Pawlotsky, J. (2003) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200312000-00012 · Cited by 79
McHutchison, J. G., Patel, K., Pockros, P. J., et al. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.09.009 · Cited by 75
Pawlotsky, J., & McHutchison, J. G. (2004) · Hepatology · doi:10.1002/hep.20065 · Cited by 65
Clinical pathways for patients with newly diagnosed hepatitis C – What actually happens
Irving, W. L., Smith, S., Cater, R. E., Pugh, S., Neal, K. R., Coupland, C. A. C., Ryder, S. D., Thomson, B. J., Pringle, M., Bicknell, M., et al. (2006) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2005.00698.x · Cited by 63
Puig‐Basagoiti, F., Forns, X., Furčić, I., Ampurdanés, S., Giménez‐Barcons, M., Franco, S., Sánchez‐Tapias, J. M., & Sáiz, J. (2005) · Journal of General Virology · doi:10.1099/vir.0.80526-0 · Cited by 61
Comparing the public health burden of chronic hepatitis C and HIV infection in France
Deuffic‐Burban, S., Wong, J. B., Valleron, A., Costagliola, D. G., Delfraissy, J., & Poynard, T. (2003) · Journal of Hepatology · doi:10.1016/j.jhep.2003.10.018 · Cited by 58
Chapel, C., Garcia, C., Bartosch, B., Roingeard, P., Zitzmann, N., Cosset, F., Dubuisson, J., Dwek, R. A., TREPO, C. G., Zoulim, F., et al. (2007) · Journal of General Virology · doi:10.1099/vir.0.82465-0 · Cited by 57
Self-citationTomei, L., Altamura, S., Paonessa, G., Francesco, R. D., & Migliaccio, G. (2005) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020501600403 · Cited by 55
Jarczak, D., Korf, M., Beger, C., Manns, M. P., & Krüger, M. (2005) · FEBS Journal · doi:10.1111/j.1742-4658.2005.04986.x · Cited by 47
Self-citationManagement of patients with chronic hepatitis C infection
Herrine, S. K., Rossi, S., & Navarro, V. J. (2006) · Clinical and Experimental Medicine · doi:10.1007/s10238-006-0089-4 · Cited by 20
Peginterferon Alpha/Ribavirin Combination Therapy for the Treatment of Hepatitis C Infection
Zic, I. (2005) · Gastroenterology Nursing · doi:10.1097/00001610-200507000-00006 · Cited by 12
Cited by
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
McHutchison, J. G., Everson, G. T., Gordon, S. C., Jacobson, I. M., Sulkowski, M., Kauffman, R., McNair, L., Alam, J., & Muir, A. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806104 · Cited by 1,089
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939
Natural products: An evolving role in future drug discovery
Mishra, B. B., & Tiwari, V. K. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.07.057 · Cited by 860
Keri, R. S., Patil, M. R., Patil, S. A., & Budagumpi, S. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.059 · Cited by 631
Metadata
- Authors
- Manns, M. P., Foster, G. R., Rockstroh, J. K., Zeuzem, S., Zoulim, F., & Houghton, M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-12
- Volume
- 6
- Issue
- 12
- Pages
- 991-1000
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2163606686
- Cited by
- 278
- References
- 55
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.